.jpg?width=1000&height=562&name=New%20Approach%20Methodologies%20(NAMs).jpg)
.png?width=1280&height=720&name=hubspot_featured_image_1200x628%20(1).png)
Scaling iPSC Manufacturing: From Cell Line Development to Clinical-Production
Learn how to scale iPSC manufacturing from clinical cell line development and gene editing to GMP cell banking and bioreactor expansion.
27 August 2026
Why PBMCs matter in gene and cell therapies
Explore the vital role of PBMCs in gene therapy and translational research, highlighting their importance in understanding immune responses and treatment efficacy.
23 July 2026
Empowering the Future of Gene Editing with StemEdit OC-1 Protein
Discover the innovative StemEdit OC-1 Protein, a generative AI-designed gene-editing enzyme that enhances genome engineering with improved safety and efficiency.
20 July 2026
.png?width=756&height=425&name=hubspot_featured_image_1200x628%20(1).png)
AI-Designed CRISPR Enables Hypoimmune iPSC Engineering for Off-the-Shelf Cell Therapy
REPROCELL's StemEdit platform enables the creation of hypoimmune iPSCs for scalable off-the-shelf cell therapies, reducing immune rejection and enhancing patient access.
04 June 2026
What Are Off-Target Effects in Cellular Gene Editing? Risks, Detection, and Solutions
Explore off-target effects in gene editing, from CRISPR risks and AI-driven detection to genomic safety in iPSC therapies.
20 May 2026
5 Hard Truths About Bringing Stem Cell Therapies to the Clinic
Discover the essential truths behind developing clinical-grade stem cell therapies and learn how to navigate the complexities of GMP manufacturing successfully.
30 March 2026
OpenCRISPR-1: The First AI-Designed CRISPR Editor for High-Precision Gene & Cell Therapy
Discover OpenCRISPR-1 — the first fully AI-designed CRISPR–Cas editor. Built by generative large language model, it enables high-efficiency, high-specificity genome and base editing in human cells. Ideal for cell therapy, stem-cell research, and advanced gene-editing workflows.
16 December 2025
Key Challenges in Clinical iPSC Applications: How REPROCELL Helps You Succeed
Overcome key challenges in clinical iPSC applications with REPROCELL's ethical sourcing, advanced reprogramming, and tailored solutions for reliable, scalable therapies.
12 May 2025
The Therapeutic Advantage of Induced Pluripotent Stem Cells-Derived Mesenchymal Stem Cells (iMSCs)
Discover the clinical benefits and advancements of using induced pluripotent stem cells-derived mesenchymal stem cells (iMSCs) in regenerative medicine and therapeutic applications.
24 February 2025
Editing B2M and CIITA to Create Hypoimmune Cell Lines for Cell Therapy
Gene editing is a viable approach for reducing immunogenicity of iPSC-derived therapeutic cells. The B2M and CIITA HLA-regulatory genes are good targets.
29 August 2023
How digital droplet PCR can improve CRISPR gene editing (with examples)
Looking to understand how digital PCR can improve your genome editing projects? Learn how digital PCR can improve your CRISPR gene editing (with examples).
05 October 2021
What is digital droplet PCR and how can it improve stem cell therapies?
Discover the definition of digital droplet PCR and how can it improve the safety of your stem cell therapies.
13 September 2021
Three challenges facing the introduction of iPSC-derived therapies
Discover three of the main challenges facing the introduction of iPSC-derived therapies on the REPROCELL blog.
12 February 2020